

In the claims:

1. (currently amended) A method for treating rosacea, in a subject in need of such treatment, comprising administering topically to the skin of said subject, for such period of time as is required to elicit the desired therapeutic response, a composition comprising a therapeutically or cosmetically-effective amount of at least one alpha-1 adrenoreceptor agonist and a carrier, wherein said therapeutically effective amount of said at least one alpha-1 adrenoreceptor agonist treats rosacea.
2. (canceled)
3. (original) The method according to claim 1, wherein said, the alpha-1 adrenoreceptor agonist comprises oxymetazoline.
4. (original) The method according to claim 1, wherein said, the alpha-1 adrenoreceptor agonist comprises tetrahydrozoline.
5. (original) The method according to claim 1, wherein said, the alpha-1 adrenoreceptor agonist comprises naphazoline.
6. (original) The method according to claim 1, wherein said the alpha-1 adrenoreceptor agonist comprises xylometazoline.
- 7.-12. (canceled)
13. (original) The method according to claim 1, wherein at least one alpha-1 adrenoreceptor agonist is co-administered with a therapeutically effective amount of at least one other active agent selected from the group consisting of antibacterial agents, antiparasitic agents, antifungal agents, anti-inflammatory agents, antihistamines, anti-pruriginous agents, anesthetics, antiviral agents, keratolytic agents, anti free-radical agents, antiseborrheic agents, antidandruff agents, antiacne agents, sunscreens and sun blocking agents, and active agents which modify at least one of cutaneous differentiation, proliferation, and pigmentation.
14. (currently amended) The method according to claim 1, wherein said composition at least one alpha-1 adrenoreceptor agonist is administered in a pharmacologically or cosmetically acceptable form selected from the group consisting of solutions, gels, lotions, creams, ointments, foams, emulsions, microemulsions, milks, serums, aerosols, sprays, dispersions, microcapsules, vesicles and microparticles thereof.

15. (currently amended) The method according to claim 1, wherein said ~~composition at least one alpha-1 adrenoreceptor agonist is administered in a pharmacologically or cosmetically acceptable form~~ selected from the group consisting of soaps and cleansing bars.

16. (currently amended) The method according to claim 1, wherein said rosacea is elicited by at least one factor selected from the group consisting of intake of food, of hot or alcoholic drinks, temperature variations, heat, exposure to ultraviolet or infrared radiation, exposure to low relative humidity, exposure of the skin to strong winds or currents of air, exposure of the skin to surfactants, irritants, irritant dermatological topical agents, and ~~or~~ cosmetics.

17.-24. (canceled)